20 results
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
its resources on its immediate goals addressing CSU and HS, we continue to assess and monitor the value of pursuing additional areas and applications
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
long-term safety of vilobelimab Test durability of response with lower maintenance therapy in OLE Main Goals Placebo n=36 Vilobelimab minimal dose
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
7:05am
and hematology. While InflaRx intends to focus its resources on its immediate goals with CSU and HS, it also assesses pursuit of these additional areas via
6-K
EX-99.2
5ol 33r04vhb78
15 Nov 21
Current report (foreign)
7:36am
6-K
q099i rkqiyh5k
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
9okkdfz
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.1
5is9prnmh4d
9 Apr 20
Controlling inflammation LIFESCI CAPITAL ALPHA SERIES CONFERENCE 2020
7:26am
6-K
EX-99.3
pmnqwckmrxkul3
26 Feb 20
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
7:15am
6-K
EX-99.1
exhz 49qeld7yqqq36fb
16 Jan 20
CONTROLLING INFLAMMATION JP Morgan Corporate Presentation January 2020
4:11pm
6-K
EX-99.1
4mt6w
14 Nov 19
Current report (foreign)
4:10pm
6-K
EX-99.1
92p hya0gvlz3xq5ynw
8 May 19
IFX-1 C5a Controlling inflammation Corporate Presentation May 2019
6:02am
20-F/A
i809ao9p
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
jukoz7xhgz9os4hwv7c
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
fnscg s5o7dxx
2 May 18
Registration statement (foreign)
7:10am
20-F
i01lci7j265q9zu
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next